In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

Annals of Surgical Oncology

Volumn 22, Issue 2, 2015, Pages 475-481

  Read, Rebecca L ^a,b   Haydu, Lauren ^a   Saw, Robyn P M ^a,b,c   Quinn, Michael J ^a,b,c   Shannon, Kerwin ^a,b,c   Spillane, Andrew J ^a,b,c   Stretch, Jonathan R ^a,b,c   Scolyer, Richard A ^a,b,c   Thompson, John F ^a,b,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CUTANEOUS MELANOMA; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IN-TRANSIT METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; TUMOR BIOPSY; INCIDENCE; LYMPH NODE METASTASIS; MELANOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR; TUMOR SEEDING; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM SEEDING; PROGNOSIS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84921935903     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4100-0     Document Type: Article

References (26)

1. Coit D, Ferrone C. Recurrent regional metastases of melanoma. In: Balch C, Houghton AN, Sober AJ, Soong SJ, Atkins MA, Thompson JF, eds. Cutaneous melanoma. 5th ed. St Louis: Quality Medical Publishing; 2009. p. 487–98.
2. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science. 2002;296(5574):1811–2.
3. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569–85.
4. McCarthy WH. Melanoma: margins for error—another view. ANZ J Surg. 2002;72:304–6.
5. Wilmott J, Haydu L, Bagot M, et al. Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology. 2012;61:889–98.
6. Heenan PJ, Ghaznawie M. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg. 1999;52:209–13.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
8. Weide B, Faller C, Buttner P, et al. Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. PLoS One. 2013;8:e63137.
9. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.
10. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.
11. van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:597–608.
12. Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg. 2004;30(2 Pt 2):244–7.
13. Heenan PJ, English DR, Holman CD, Armstrong BK. The effects of surgical treatment on survival and local recurrence of cutaneous malignant melanoma. Cancer. 1992;69:421–6.
14. Suojarvi NJ, Jahkola TA, Virolainen S, Ilmonen SK, Hernberg MM. Outcome following local recurrence or in-transit metastases in cutaneous melanoma. Melanoma Res. 2012;22:447–53.
15. Kretschmer L, Beckmann I, Thoms KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol. 2006;13:1105–12.
16. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–96.
17. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23:4588–90.
18. Veenstra HJ, van der Ploeg IM, Wouters MW, Kroon BB, Nieweg OE. Reevaluation of the locoregional recurrence rate in melanoma patients with a positive sentinel node compared to patients with palpable nodal involvement. Ann Surg Oncol. 2010;17:521–6.
19. Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17:709–17.
20. Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247:1003–10.
21. Veenstra HJ, Wouters MJ, Kroon BB, Olmos RA, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454–7.
22. Miller MW, Vetto JT, Monroe MM, Weerasinghe R, Andersen PE, Gross ND. False-negative sentinel lymph node biopsy in head and neck melanoma. Otolaryngol Head Neck Surg. 2011;145:606–11.
23. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429–39.
24. Beasley GM, Speicher P, Sharma K, et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686–92.
25. Thompson JF. Local and regional therapies for melanoma: many arrows in the quiver. J Surg Oncol. 2014;109:295.
26. Espinosa E, Grob JJ, Dummer R, et al. Treatment algorithms in stage IV melanoma. Am J Ther. In press.